Glycemic Management in Insulin-Naive Patients in the Inpatient Setting
- PMID: 38756429
- PMCID: PMC11093763
- DOI: 10.2337/ds23-0007
Glycemic Management in Insulin-Naive Patients in the Inpatient Setting
Abstract
Objective: The ideal inpatient insulin regimen efficiently attains the target blood glucose range, effectively treats hyperglycemia, and minimizes the risk of hypoglycemia. The objective of this study was to compare glycemic targets achieved by using correctional monotherapy (CM) and basal-bolus therapy (BBT) in insulin-naive patients in the inpatient setting to determine optimal blood glucose management for these patients.
Design: This was a retrospective observational cohort study of 792 patients with diabetes not on home insulin therapy who were admitted to an academic hospital over a 5.5-month period. The percentages of hyperglycemic and hypoglycemic values in each group were compared.
Results: Among the 3,112 measured blood glucose values obtained from 792 patients within the first 24 hours of insulin administration, 28.5% were hyperglycemic in the BBT group compared with 23.5% in the CM group. When adjusted for covariates, there was a 23% decrease in hyperglycemia in the BBT group (incidence rate ratio = 0.77, 95% CI 0.64-0.95, P = 0.006). Increases in A1C and admission blood glucose, as well as decreases in admission creatinine and inpatient steroid use, were independently associated with higher rates of hyperglycemia, adjusted for all other covariates. There was no significant difference between the groups in the rate of hypoglycemia in the first 24 hours, which was 1.9% in the BBT group and 1.4% in the CM group (P = 0.301).
Conclusion: Utilizing BBT in insulin-naive patients admitted to the hospital within the first 24 hours of insulin administration results in lower rates of hyperglycemia without higher rates of hypoglycemia when compared with CM.
© 2024 by the American Diabetes Association.
Conflict of interest statement
No potential conflicts of interest relevant to this article were reported.
Similar articles
-
Reliability of Inpatient CGM: Comparison to Standard of Care.J Diabetes Sci Technol. 2023 Mar;17(2):329-335. doi: 10.1177/19322968211062168. Epub 2021 Dec 15. J Diabetes Sci Technol. 2023. PMID: 34911384 Free PMC article.
-
Comparative Efficacy and Safety of Basal/Correctional Vs Basal/Bolus/Correctional Insulin Regimens in Medical Intensive Care Unit Patients Receiving Continuous Enteral Nutrition.Ann Pharmacother. 2025 May 25:10600280251340180. doi: 10.1177/10600280251340180. Online ahead of print. Ann Pharmacother. 2025. PMID: 40415226
-
Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.Clin Ther. 2010 May;32(5):896-908. doi: 10.1016/j.clinthera.2010.05.001. Clin Ther. 2010. PMID: 20685497 Clinical Trial.
-
Addressing hyperglycemia from hospital admission to discharge.Curr Med Res Opin. 2010 Mar;26(3):589-98. doi: 10.1185/03007990903566822. Curr Med Res Opin. 2010. PMID: 20078323 Review.
-
Practical implications of the revised guidelines for inpatient glycemic control.Pol Arch Med Wewn. 2009 Dec;119(12):801-9. Pol Arch Med Wewn. 2009. PMID: 20010466 Review.
References
-
- Centers for Disease Control and Prevention . National Diabetes Statistics Report, 2020: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2020
-
- Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978–982 - PubMed
LinkOut - more resources
Full Text Sources